Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2011

01.07.2011 | Breast Oncology

Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration

verfasst von: Jennifer L. Gnerlich, MD, Anjali D. Deshpande, PhD, MPH, Donna B. Jeffe, PhD, Susmitha Seelam, MSPH, Eric Kimbuende, MSPH, Julie A. Margenthaler, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Male breast cancer accounts for less than 1% of all breast cancers, yet males have a worse prognosis than females with breast cancer.

Methods

Using the 1988–2003 Surveillance, Epidemiology, and End Results Program data, we conducted a retrospective, population-based cohort study to investigate stage-specific differences in breast cancer-specific and all-cause mortality between males and females. We calculated adjusted hazard ratios (aHR) and 95% confidence intervals (CI) using Cox regression models to compare breast cancer-specific and all-cause mortality by stage between males and females, controlling for potential confounding variables.

Results

There were 246,059 patients with a first, single, primary breast cancer [1,541 (0.6%) male; 244,518 (99.4%) female]. Compared with females, males were more likely to be older, Black, married, diagnosed at more advanced stages, and treated with mastectomy (each P < 0.001). Males also were more likely to have lower grade and estrogen/progesterone receptor-positive tumors (each P < 0.001). After controlling for confounders, males were more likely to die from their breast cancer when compared with females, only if diagnosed with stage I disease (aHR 1.72, CI 1.15–2.61). For all-cause mortality, males were more likely than females to die at each stage of disease except stage IV.

Conclusions

Although all-cause mortality was higher for men than women at all stages of nonmetastatic breast cancer, higher male breast cancer-specific mortality was attributed to poorer survival in stage I disease. However, this statistical difference is unlikely to be clinically relevant and attributable to in-stage migration.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.PubMedCrossRef
2.
Zurück zum Zitat Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51–7.PubMedCrossRef Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51–7.PubMedCrossRef
3.
Zurück zum Zitat Stang A, Thomssen C. Decline in breast cancer incidence in the United States: what about male breast cancer? Breast Cancer Res Treatment. 2008;112:595–6.CrossRef Stang A, Thomssen C. Decline in breast cancer incidence in the United States: what about male breast cancer? Breast Cancer Res Treatment. 2008;112:595–6.CrossRef
4.
Zurück zum Zitat Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treatment. 2009;115:429–30.CrossRef Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treatment. 2009;115:429–30.CrossRef
5.
Zurück zum Zitat Giordano SH. Male breast cancer: it’s time for evidence instead of extrapolation. Onkologie. 2008;31:505–6.PubMedCrossRef Giordano SH. Male breast cancer: it’s time for evidence instead of extrapolation. Onkologie. 2008;31:505–6.PubMedCrossRef
6.
Zurück zum Zitat Ciatto S, Iossa A, Bonardi R, Pacini P. Male breast carcinoma: review of amulticenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori. 1990;76:555–8.PubMed Ciatto S, Iossa A, Bonardi R, Pacini P. Male breast carcinoma: review of amulticenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori. 1990;76:555–8.PubMed
7.
Zurück zum Zitat Salvadori B, Saccozzi R, Manzari A, Andreola S, Conti RA, Cusumano F, et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer. 1994;30A:930–5.PubMedCrossRef Salvadori B, Saccozzi R, Manzari A, Andreola S, Conti RA, Cusumano F, et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer. 1994;30A:930–5.PubMedCrossRef
8.
Zurück zum Zitat Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. Cancer. 1998;83:498–509.PubMedCrossRef Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. Cancer. 1998;83:498–509.PubMedCrossRef
9.
Zurück zum Zitat Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol. 1998;24:548–52.PubMedCrossRef Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol. 1998;24:548–52.PubMedCrossRef
10.
Zurück zum Zitat Tajima N, Tsukuma H, Oshima A. Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol. 2001;11:1–7.PubMed Tajima N, Tsukuma H, Oshima A. Descriptive epidemiology of male breast cancer in Osaka, Japan. J Epidemiol. 2001;11:1–7.PubMed
11.
Zurück zum Zitat Sandler B, Carmen C, Perry RR. Cancer of the male breast. Am Surg. 1994;60:816–20.PubMed Sandler B, Carmen C, Perry RR. Cancer of the male breast. Am Surg. 1994;60:816–20.PubMed
12.
Zurück zum Zitat Thalib L, Hall P. Survival of male breast cancer patients: population-based cohort study. Cancer Sci. 2009;100:292–5.PubMedCrossRef Thalib L, Hall P. Survival of male breast cancer patients: population-based cohort study. Cancer Sci. 2009;100:292–5.PubMedCrossRef
13.
Zurück zum Zitat Borgen PI, Senie RT, McKinnon WMP, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997:4:385–88.PubMedCrossRef Borgen PI, Senie RT, McKinnon WMP, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997:4:385–88.PubMedCrossRef
14.
Zurück zum Zitat Borgen PI, Wong GY, Vlamis V, et al. Current management of breast cancer: a review of 104 cases. Ann Surg. 1992;215:451–7.PubMedCrossRef Borgen PI, Wong GY, Vlamis V, et al. Current management of breast cancer: a review of 104 cases. Ann Surg. 1992;215:451–7.PubMedCrossRef
15.
Zurück zum Zitat Levi F, Randimbison L, La VC. Breast cancer survival in relation to sex and age. Oncology. 1992;49:413–7.PubMedCrossRef Levi F, Randimbison L, La VC. Breast cancer survival in relation to sex and age. Oncology. 1992;49:413–7.PubMedCrossRef
16.
Zurück zum Zitat Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995;31A:1960–4.PubMedCrossRef Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer. 1995;31A:1960–4.PubMedCrossRef
17.
Zurück zum Zitat Anan K, Mitsuyama S, Nishihara K, et al. Breast cancer in Japanese men: does sex affect prognosis? Breast Cancer. 2004;11:180–6.PubMedCrossRef Anan K, Mitsuyama S, Nishihara K, et al. Breast cancer in Japanese men: does sex affect prognosis? Breast Cancer. 2004;11:180–6.PubMedCrossRef
18.
Zurück zum Zitat Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol. 2005;15:773–80.PubMedCrossRef Hill TD, Khamis HJ, Tyczynski JE, Berkel HJ. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol. 2005;15:773–80.PubMedCrossRef
19.
Zurück zum Zitat Adami, HO, Holmberg L. Malker B, Ries L. Long-term survival in 406 males with breast cancer. Br J Cancer. 1985;52:99–103.PubMedCrossRef Adami, HO, Holmberg L. Malker B, Ries L. Long-term survival in 406 males with breast cancer. Br J Cancer. 1985;52:99–103.PubMedCrossRef
20.
Zurück zum Zitat Atalay C, Kanlioz M, Altinok M. Prognostic factors affecting survival in male breast cancer. J Exp Clin Cancer Res. 2003;22:29–33.PubMed Atalay C, Kanlioz M, Altinok M. Prognostic factors affecting survival in male breast cancer. J Exp Clin Cancer Res. 2003;22:29–33.PubMed
21.
Zurück zum Zitat El-Tamer MB, Komenaka IK, Troxel A, et al. Men with breast cancer have better disease-specific survival than women. Arch Surg. 2004;139:1079–82.PubMedCrossRef El-Tamer MB, Komenaka IK, Troxel A, et al. Men with breast cancer have better disease-specific survival than women. Arch Surg. 2004;139:1079–82.PubMedCrossRef
23.
Zurück zum Zitat Schaub NP, Maloney N, Schneider H, Feliberti E, Perry R. Changes in male breast cancer over a 30-year period. Am Surg. 2008;74:707–12.PubMed Schaub NP, Maloney N, Schneider H, Feliberti E, Perry R. Changes in male breast cancer over a 30-year period. Am Surg. 2008;74:707–12.PubMed
24.
Zurück zum Zitat Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R. Male breast cancer in the Veterans Affairs population: a comparative analysis. Cancer. 2007;109:1471–7.PubMedCrossRef Nahleh ZA, Srikantiah R, Safa M, Jazieh AR, Muhleman A, Komrokji R. Male breast cancer in the Veterans Affairs population: a comparative analysis. Cancer. 2007;109:1471–7.PubMedCrossRef
25.
Zurück zum Zitat Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:20–26.PubMedCrossRef Weiss JR, Moysich KB, Swede H. Epidemiology of male breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:20–26.PubMedCrossRef
26.
Zurück zum Zitat Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678–687.PubMed Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678–687.PubMed
27.
Zurück zum Zitat Temmim L, Luqmani YA, Jarallah M, Juma I, Mathew M. Evaluation of prognostic factors in male breast cancer. Breast. 2001;10:166–75.PubMedCrossRef Temmim L, Luqmani YA, Jarallah M, Juma I, Mathew M. Evaluation of prognostic factors in male breast cancer. Breast. 2001;10:166–75.PubMedCrossRef
28.
Zurück zum Zitat Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat. 2004;84:215–23.PubMedCrossRef Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat. 2004;84:215–23.PubMedCrossRef
29.
Zurück zum Zitat Avisar E, McParland E, Dicostanzo D, Axelrod D. Prognostic factors in node-negative male breast cancer. Clin Breast Cancer. 2006;7:331–5.PubMedCrossRef Avisar E, McParland E, Dicostanzo D, Axelrod D. Prognostic factors in node-negative male breast cancer. Clin Breast Cancer. 2006;7:331–5.PubMedCrossRef
30.
Zurück zum Zitat Onami S, Ozaki M, Mortimer JE, Pal SK. Male breast cancer: an update in diagnosis, treatment, and molecular profiling. Maturitas. 2010;65(4):308–14.PubMedCrossRef Onami S, Ozaki M, Mortimer JE, Pal SK. Male breast cancer: an update in diagnosis, treatment, and molecular profiling. Maturitas. 2010;65(4):308–14.PubMedCrossRef
31.
Zurück zum Zitat Blin N, Kardas I, Welter C, Rys J, Niezabitowski A, Limon J, et al. Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance. Oncology. 1993;50:408–11.PubMedCrossRef Blin N, Kardas I, Welter C, Rys J, Niezabitowski A, Limon J, et al. Expression of the c-erbB2 proto-oncogene in male breast carcinoma: lack of prognostic significance. Oncology. 1993;50:408–11.PubMedCrossRef
32.
Zurück zum Zitat Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104:2359–64.PubMedCrossRef Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104:2359–64.PubMedCrossRef
33.
Zurück zum Zitat Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992;65:252–4.PubMedCrossRef Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer. 1992;65:252–4.PubMedCrossRef
34.
Zurück zum Zitat Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85:629–39.PubMedCrossRef Goss PE, Reid C, Pintilie M, Lim R, Miller N. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85:629–39.PubMedCrossRef
35.
Zurück zum Zitat Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol. 2002;15:853–61.PubMedCrossRef Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol. 2002;15:853–61.PubMedCrossRef
36.
Zurück zum Zitat Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232–9.PubMedCrossRef Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28:232–9.PubMedCrossRef
37.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–73.PubMedCrossRef Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–73.PubMedCrossRef
38.
Zurück zum Zitat Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001;6:133–146.PubMedCrossRef Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001;6:133–146.PubMedCrossRef
39.
Zurück zum Zitat Wang J, Kollias J, Marsh C, Maddern G. Are males with early breast cancer treated differently from females with early breast cancer in Australia and New Zealand? Breast (Edinburgh). 2009;18:378–81. Wang J, Kollias J, Marsh C, Maddern G. Are males with early breast cancer treated differently from females with early breast cancer in Australia and New Zealand? Breast (Edinburgh). 2009;18:378–81.
40.
Zurück zum Zitat Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, Naessens JM, et al. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol. 1993;2:325–33.PubMedCrossRef Gough DB, Donohue JH, Evans MM, Pernicone PJ, Wold LE, Naessens JM, et al. A 50-year experience of male breast cancer: is outcome changing? Surg Oncol. 1993;2:325–33.PubMedCrossRef
41.
Zurück zum Zitat Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast (Edinburgh). 2007;16:653–6. Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast (Edinburgh). 2007;16:653–6.
42.
Zurück zum Zitat Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States. Cancer Cause Control. 2004;15:1027–34.CrossRef Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States. Cancer Cause Control. 2004;15:1027–34.CrossRef
Metadaten
Titel
Poorer Survival Outcomes for Male Breast Cancer Compared with Female Breast Cancer May Be Attributable to In-Stage Migration
verfasst von
Jennifer L. Gnerlich, MD
Anjali D. Deshpande, PhD, MPH
Donna B. Jeffe, PhD
Susmitha Seelam, MSPH
Eric Kimbuende, MSPH
Julie A. Margenthaler, MD
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2011
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1468-3

Weitere Artikel der Ausgabe 7/2011

Annals of Surgical Oncology 7/2011 Zur Ausgabe

Translational Research and Biomarkers

Personalizing Thyroid Cancer Care: Are We There Yet?

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.